Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.48 |
| ▸ | SLC27A2 | O14975 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462531 | 0.85 | CMA1 (0.46) | IDO1LMNAADAMTS5SLC27A2MAPT | |
| SCHEMBL16412396 | 0.85 | CMA1 (0.46) | IDO1LMNAADAMTS5SLC27A2MAPT | |
| SCHEMBL5873792 | 0.78 | LMNA (0.50) | LMNAADAMTS5SLC27A2MAPTALDH1A1 | |
| SCHEMBL2265588 | 0.78 | IDO1 (0.53) | IDO1ADAMTS5MAPTGAAMEN1 | |
| SCHEMBL2827536 | 0.78 | CYP1A2 (0.57) | IDO1MAPTKMT2AAKR1B1CYP2C19 | |
| SCHEMBL31472154 | 0.78 | ALDH1A1 (0.44) | IDO1LMNAADAMTS5SLC27A2MAPT | |
| SCHEMBL246962 | 0.77 | IDO1 (0.56) | IDO1LMNAMAPTALDH1A1KDM4E | |
| SCHEMBL25115048 | 0.77 | IDO1 (0.43) | IDO1LMNAADAMTS5MAPTALDH1A1 | |
| SCHEMBL15715190 | 0.77 | CYP1A2 (0.56) | IDO1LMNAADAMTS5MAPTALDH1A1 | |
| SCHEMBL30548920 | 0.77 | IDO1 (0.43) | IDO1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250163016-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4467537-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-117157288-A | Pyridine derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11793815-B2 | Oxindoles and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-116802176-A | Oxindoles and methods of use thereof | 阿利戈斯治疗公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4240722-A1 | OXINDOLES AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| WO-2014090692-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | IDO1 4019/4885LMNA 3109/4885ADAMTS5 3427/4885 |
| US-11793815-B2 | Oxindoles and methods of use thereof | CYP11B2, OXTR, CYP11B1 | IDO1 246/4885LMNA 2925/4885ADAMTS5 374/4885 |
| US-20250163016-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | KDM1B, KDM1A, EZH2 | IDO1 617/4885LMNA 1458/4885ADAMTS5 4188/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | IDO1 4019/4885LMNA 3109/4885ADAMTS5 3427/4885 |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, NOD1 | IDO1 1883/4885LMNA 1687/4885ADAMTS5 3063/4885 |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | IDO1 2746/4885LMNA 1417/4885ADAMTS5 904/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | IDO1 1949/4885LMNA 2681/4885ADAMTS5 3949/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | IDO1 367/4885LMNA 2978/4885ADAMTS5 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.